Stephen B. H. Kent
Corporate Officer/Principal chez The University of Chicago
Profil
Stephen B.
H.
Kent was the founder of Gryphon Therapeutics, Inc. (founded in 1994) where he held the title of Chief Scientific Officer from 1994 to 2002.
Dr. Kent is also the founder of Opal Therapeutics Pty Ltd.
Dr. Kent's current jobs include being the Director-Institute Biophysical Dynamics at The University of Chicago since 2001 and the Director-Center Functional Genomics at Victoria University of Wellington since 2004.
Dr. Kent's former jobs include being the Lead Independent Director at Enzo Biochem, Inc. in 2012 and being a Director at Ciphergen Biosystems KK from 1994 to 1997.
Dr. Kent obtained his doctorate degree from the University of California, Berkeley.
Postes actifs de Stephen B. H. Kent
| Sociétés | Poste | Début |
|---|---|---|
| The University of Chicago | Corporate Officer/Principal | 01/01/2001 |
| Victoria University of Wellington | Corporate Officer/Principal | 01/01/2004 |
Anciens postes connus de Stephen B. H. Kent
| Sociétés | Poste | Fin |
|---|---|---|
Gryphon Therapeutics, Inc.
 Gryphon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Gryphon Therapeutics, Inc. develops and produces protein therapeutics. Its products combine chemically synthesized protein backbones with polyethylene glycols, such as molecules to create potent medications. Gryphon Therapeutics was founded in 1993 and is headquartered in South San Francisco, CA | Fondateur | 01/01/2002 |
Ciphergen Biosystems KK
 Ciphergen Biosystems KK Electronic Equipment/InstrumentsElectronic Technology Ciphergen Biosystems KK markets and supplies protein chip systems and services for clinical, research and process proteomic applications. The company was founded in January, 1999 and is headquartered in Yokohama, Japan. | Directeur/Membre du Conseil | 01/01/1997 |
Opal Therapeutics Pty Ltd.
 Opal Therapeutics Pty Ltd. Pharmaceuticals: MajorHealth Technology Opal Therapeutics Pty Ltd develops immunotherapy for HIV and Hepatitis C & chronic infection. The company was founded in 2005 and is headquartered in Melbourne, Australia. | Fondateur | - |
| ENZO BIOCHEM, INC. | Directeur/Membre du Conseil | - |
Formation de Stephen B. H. Kent
| University of California, Berkeley | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ENZO BIOCHEM, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Gryphon Therapeutics, Inc.
Gryphon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Gryphon Therapeutics, Inc. develops and produces protein therapeutics. Its products combine chemically synthesized protein backbones with polyethylene glycols, such as molecules to create potent medications. Gryphon Therapeutics was founded in 1993 and is headquartered in South San Francisco, CA | Health Technology |
Ciphergen Biosystems KK
Ciphergen Biosystems KK Electronic Equipment/InstrumentsElectronic Technology Ciphergen Biosystems KK markets and supplies protein chip systems and services for clinical, research and process proteomic applications. The company was founded in January, 1999 and is headquartered in Yokohama, Japan. | Electronic Technology |
Opal Therapeutics Pty Ltd.
Opal Therapeutics Pty Ltd. Pharmaceuticals: MajorHealth Technology Opal Therapeutics Pty Ltd develops immunotherapy for HIV and Hepatitis C & chronic infection. The company was founded in 2005 and is headquartered in Melbourne, Australia. | Health Technology |